Trial intelligence / Profile preview

Phase III randomized study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia

2013-003586-34Phase 3Completed

Sponsor: Cyclacel Pharmaceuticals, Inc.
Start: Dec 2013
Modality: Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of sapacitabine and decitabine in acute myeloid leukemia (AML) (3 arms), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Overall survival. Started Dec 2013; status: completed.

Drugs

sapacitabinedecitabine

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on 2013-003586-34.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-003586-34.